11.29.22
Edwards Lifesciences released one-year results for its TRISCEND study of the EVOQUE transcatheter tricuspid valve replacement system at PCR London Valves 2022 this week.
The 176 patients enrolled in the study had symptomatic moderate of greater functional or degenerative tricuspid regurgitation (TR), despite optimal therapy. This represented the largest dataset among transcatheter tricuspid valve replacement therapies.
The one-year outcomes showed:
"Tricuspid regurgitation is prevalent, undertreated and has a significant impact on patients' quality of life. With most TR patients at high risk for surgery, there is a great need for an approved transcatheter valve replacement treatment option," Prof. Didier Tchetche, MD, Clinique Pasteur, Toulouse, France and TRISCEND study co-primary investigator told the press. "The one-year results for patients who received the EVOQUE tricuspid valve replacement as part of the TRISCEND study provide important support for our confidence in this therapy as an option for patients who suffer from tricuspid regurgitation."
"We are encouraged by the sustained safety and performance outcomes demonstrated by the EVOQUE system at one year, as it represents a meaningful therapy in our portfolio of transcatheter therapies being developed to help improve the quality-of-life for patients with tricuspid and mitral valve diseases," said Bernard J. Zovighian, Edwards' corporate VP, transcatheter mitral and tricuspid therapies. "Edwards' eight data presentations included in this year's PCR London Valves program deliver on our long-term investment in innovation and clinical evidence generation to meet the needs of patients and mark a new era for our company."
The 176 patients enrolled in the study had symptomatic moderate of greater functional or degenerative tricuspid regurgitation (TR), despite optimal therapy. This represented the largest dataset among transcatheter tricuspid valve replacement therapies.
The one-year outcomes showed:
- High survival of 90.1% and high freedom from heart failure hospitalization at 88.4%
- Significant and sustained TR reduction, with 97.6% of patients with mild or trace TR (n=84)
- Significantly improved functional and quality-of-life outcomes, with 93% of patients in NYHA Class I or II compared to 26% at baseline (n=89) and a 26-point increase in KCCQ score over baseline (n=102)
"Tricuspid regurgitation is prevalent, undertreated and has a significant impact on patients' quality of life. With most TR patients at high risk for surgery, there is a great need for an approved transcatheter valve replacement treatment option," Prof. Didier Tchetche, MD, Clinique Pasteur, Toulouse, France and TRISCEND study co-primary investigator told the press. "The one-year results for patients who received the EVOQUE tricuspid valve replacement as part of the TRISCEND study provide important support for our confidence in this therapy as an option for patients who suffer from tricuspid regurgitation."
"We are encouraged by the sustained safety and performance outcomes demonstrated by the EVOQUE system at one year, as it represents a meaningful therapy in our portfolio of transcatheter therapies being developed to help improve the quality-of-life for patients with tricuspid and mitral valve diseases," said Bernard J. Zovighian, Edwards' corporate VP, transcatheter mitral and tricuspid therapies. "Edwards' eight data presentations included in this year's PCR London Valves program deliver on our long-term investment in innovation and clinical evidence generation to meet the needs of patients and mark a new era for our company."